Charles River Laboratories International (CNSX:CRL) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.
Earnings & Valuation
This table compares Charles River Laboratories International and dorsaVi's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Charles River Laboratories International | N/A | N/A | N/A | N/A | N/A |
dorsaVi | $1.65 million | 0.00 | $-3,158,396.93 | A($0.01) | N/A |
Charles River Laboratories International has higher earnings, but lower revenue than dorsaVi.
Profitability
This table compares Charles River Laboratories International and dorsaVi's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Charles River Laboratories International | N/A | N/A | N/A |
dorsaVi | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent recommendations for Charles River Laboratories International and dorsaVi, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Charles River Laboratories International | 0 | 0 | 0 | 0 | N/A |
dorsaVi | 0 | 0 | 0 | 0 | N/A |
Summary
dorsaVi beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.